- South Korea
- /
- Pharma
- /
- KOSE:A001630
We Think That There Are Some Issues For Chong Kun Dang Holdings (KRX:001630) Beyond Its Promising Earnings
Chong Kun Dang Holdings Corp.'s (KRX:001630) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being concerned with what they see.
View our latest analysis for Chong Kun Dang Holdings
The Impact Of Unusual Items On Profit
To properly understand Chong Kun Dang Holdings' profit results, we need to consider the ₩34b gain attributed to unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. Which is hardly surprising, given the name. Chong Kun Dang Holdings had a rather significant contribution from unusual items relative to its profit to September 2024. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.
That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.
Our Take On Chong Kun Dang Holdings' Profit Performance
As we discussed above, we think the significant positive unusual item makes Chong Kun Dang Holdings' earnings a poor guide to its underlying profitability. As a result, we think it may well be the case that Chong Kun Dang Holdings' underlying earnings power is lower than its statutory profit. But at least holders can take some solace from the 12% EPS growth in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. For example, we've found that Chong Kun Dang Holdings has 4 warning signs (2 make us uncomfortable!) that deserve your attention before going any further with your analysis.
This note has only looked at a single factor that sheds light on the nature of Chong Kun Dang Holdings' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A001630
Chong Kun Dang Holdings
Manufactures and distributes pharmaceutical products in South Korea and internationally.
Good value slight.